氘可来昔替尼治疗银屑病的效果怎么样?

A trial to compare the efficacy and safety of the oral, selective, allosteric tyrosine kinase 2 inhibitor deuterated colexitinib with placebo and apremilast in adults with moderate to severe plaque psoriasis.

Methods: In the 52-week, double-blind, phase 3 POETYK PSO-1 trial (NCT03624127), participants were randomized 2:1:1 to decoxitinib 6 mg daily (n=332), placebo (n=166), or apremilast 30 mg twice daily (n=168). Co-primary endpoints include a ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and Static Physician Global Assessment score of 0 or 1 (sPGA 0/1) with colexitinib compared with placebo at Week 16.

Results: At week 16, colexitinib was effective compared with placebo or apremilast on PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001. The incidence of adverse events was similar for colexitinib and placebo and apremilast.

Conclusion: Deuterated colexitinib is superior to placebo and apremilast on multiple efficacy endpoints and is well tolerated in moderate to severe plaque psoriasis.

Psoriasis is a chronic immune-mediated disease. Deuterated colexitinib can reduce the inflammatory response by inhibiting the production of inflammatory factors, thereby reducing the redness, swelling, itching and other symptoms of psoriasis patients. Deuterated coxitinib can regulate cell proliferation and differentiation programs and reduce abnormal proliferation of epidermal cells, thereby alleviating the symptoms of psoriasis. Deuterated coxitinib has fewer adverse reactions in the treatment of psoriasis. It can not only effectively relieve symptoms, but also improve the patient's quality of life.

Common adverse reactions of deuterated colexitinib include upper respiratory tract infection, elevated blood creatine phosphokinase, herpes simplex, oral ulcers, folliculitis, acne, etc. Patients have different conditions and constitutions, and the adverse reactions after taking the drug are also different. It is recommended that patients follow the doctor's instructions and receive symptomatic treatment.

Recommended related articles:

References

Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. PMID: 35820547.